Matches in Nanopublications for { ?s ?p "DDI between Fluoxetine and Cilostazol - Fluoxetine, a moderate CYP2C19 inhibitor, may decrease the metabolism of cilostazol. Monitor for changes in the therapeutic and adverse effects of cilostazol if fluoxetine is initiated, discontinued or dose changed. [drugbank_resource:DB00472_DB01166]"@en ?g. }
Showing items 1 to 1 of
1
with 100 items per page.
- drugbank_resource:DB00472_DB01166 label "DDI between Fluoxetine and Cilostazol - Fluoxetine, a moderate CYP2C19 inhibitor, may decrease the metabolism of cilostazol. Monitor for changes in the therapeutic and adverse effects of cilostazol if fluoxetine is initiated, discontinued or dose changed. [drugbank_resource:DB00472_DB01166]" assertion.